Aryl aniline β2 adrenergic receptor agonists

A compound of formula (I):

• wherein:
• each of R1-R5 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, and Ra;
• or R1 and R2, R2 and R3, R3 and R4, or R4 and R5 are joined together to form a group selected from the group consisting of —C(Rd)═C(Rd)C(═O)NRd—, —CRdRd—CRdRd—C(═O)NRd—, —NRdC(═O)C(Rd)═C(Rd), —NRdC(═O)CRdRd—CRdRd—, —NRdC(═O)S—, —SC(═O)NRd—, —(CRdRd)p—, —S(CRdRd)q—, —(CRdRd)qS—, —S(CRdRd)rO—, —O(CRdRd)rS—, and —NHC(Rj)═C(Rk)—;
• R6 is hydrogen, alkyl, or alkoxy;
• R7 is hydrogen or alkyl;
• R8 is hydrogen or alkyl;
• or R8 together with R9 is —CH2— or —CH2CH2—;
• R9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, and Ra, or R9 together with R8 is —CH2— or —CH2CH2—;
• R10 is hydrogen or alkyl;
• each R11, R12, and R13 is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, —NO2, halo, —NRdRe, —C(═O)Rd, —CO2Rd—OC(═O)Rd, —CN, —C(═O)NRdRe, —NRdC(═O)Re, —OC(═O)NRdRe, —NRdC(═O)ORe, —NRdC(═O)NRdRe, —ORd, —S(O)mRd, —NRd—NRd—C(═O)Rd, —NRd—N═CRdRd, —N(NRdRe)Rd, and —S(O)2NRdRe;
• or R11 and R12 together with the atoms to which they are attached form a fused benzo ring, which benzo ring can optionally be substituted with 1, 2, 3, or 4 Rc;
• or R11 and R12 together with the atoms to which they are attached form a heterocyclic ring;
• wherein for R1-R6, R9, and R11-R13, each alkyl, alkenyl, and alkynyl is optionally substituted with Rm, or with 1, 2, 3, or 4 substituents independently selected from Rb;
• for R1-R6, R9, and R11-R13, each aryl and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rc, and for R1-R6, R9, and R11-R13 each cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rb and Rc;
• each Ra is independently —ORd, —NO2, halo, —S(O)mRd, —S(O)2ORd, —S(O)mNRdRe, —NRdRe, —O(CRfRg)nNRdRe, —C(═O)Rd, —CO2Rd, —CO2(CRfRg)—CONRdRe, —OC(═O)Rd, —CN, —C(═O)NRdRe, —NRdC(═O)Re, —OC(═O)NRdRe, —NRdC(═O)ORe, —NRdC(═O)NRdRe, —CRd(═N—ORe), —CF3, or —OCF3;
• each Rb is independently Ra, oxo, or ═N—ORc;
• each Rc is independently Ra, alkyl, alkenyl, or alkynyl;
• wherein each alkyl, alkenyl and alkynyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rb;
• each Rd and Re is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl;
• wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh;
• or Rd and Re together with the atoms to which they are attached form a heterocyclic ring having from 5 to 7 ring atoms, wherein the heterocyclic ring optionally contains 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen;
• each Rf and Rg is independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl;
• wherein each alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh;
• or Rf and Rg together with the carbon atom to which they are attached form a ring having from 5 to 7 ring atoms, wherein the ring optionally contains 1 or 2 heteroatoms independently selected from oxygen, sulfur or nitrogen;
• each Rh is independently halo, C1-8alkyl, C1-8alkoxy, —S—C1-8alkyl, aryl, (aryl)-C1-6alkyl, (aryl)-C1-8alkoxy, heteroaryl, (heteroaryl)-C1-6alkyl, (heteroaryl)-C1-8alkoxy, hydroxy, amino, —NHC1-6alkyl, —N(C1-6alkyl)2, —OC(═O)C1-6alkyl, —C(═O)C1-6 halkyl, —C(═O)OC1-6alkyl, —NHC(═O)C1-6alkyl, —C(═O)NHC1-6alkyl, carboxy, nitro, —CN, or —CF3;
• Rj and Rk together with the carbon atoms to which they are attached form a phenyl ring that is optionally substituted with 1, 2, 3, or 4 Rc;
• each Rm is independently aryl, heteroaryl, cycloalkyl or heterocyclyl;
• wherein each aryl or heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of Rc, and wherein each cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents selected from Rb;
• m is 0, 1, or 2;
• n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
• p is 3, 4, or 5;
• q is 2, 3, or 4;
• r is 1, 2, or 3;
• and
• w is 0, 1, 2, 3, or 4;
• or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.